Extracorporeal Photopheresis (ECP) Therapy with UVADEX (R) (methoxsalen) Improved Quality of Life (QoL) for National Institutes of Health (NIH)-graded Moderate to Severe Chronic Graft-vs-Host Disease (cGvHD)

MLA

Jagasia, Madan, et al. Extracorporeal Photopheresis (ECP) Therapy with UVADEX (R) (Methoxsalen) Improved Quality of Life (QoL) for National Institutes of Health (NIH)-Graded Moderate to Severe Chronic Graft-vs-Host Disease (CGvHD). 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1201318384&authtype=sso&custid=ns315887.

APA

Jagasia, M., Greinix, H., Scheid, C., Socie, G., Ayuk, F., Tischer, J., Donato, M., Batai, A., Chen, H., Chen, S.-C., Chin, T., Boodee, H., & Mitri, G. (2018). Extracorporeal Photopheresis (ECP) Therapy with UVADEX (R) (methoxsalen) Improved Quality of Life (QoL) for National Institutes of Health (NIH)-graded Moderate to Severe Chronic Graft-vs-Host Disease (cGvHD).

Chicago

Jagasia, Madan, Hildegard Greinix, Christoph Scheid, Gerard Socie, Francis Ayuk, Johanna Tischer, Michele Donato, et al. 2018. “Extracorporeal Photopheresis (ECP) Therapy with UVADEX (R) (Methoxsalen) Improved Quality of Life (QoL) for National Institutes of Health (NIH)-Graded Moderate to Severe Chronic Graft-vs-Host Disease (CGvHD).” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1201318384&authtype=sso&custid=ns315887.